Table 1 |
||||||
|
Clinical features of the 44 reported cases of uterine PEComa*** |
||||||
| REFERENCE |
Year |
Age (yrs) |
TSC |
Location |
Management |
Outcome |
|
|
||||||
| Hornick & Fletcher (39) |
2008 |
34 |
NS |
Corpus |
NS |
NERM at 33 months |
| Armah & Parwani (40) |
2008 |
59 |
No |
Corpus |
Hysterectomy/BSO performed 7-years previously for presumed leiomyosarcoma; Renal and pulmonary metastases at current presentation; all resected |
NERM at 15 months |
| Liang et al (41) |
2008 |
59 |
Yes |
Corpus |
Hysterectomy/BSO/Pelvic and paraaortic Lymphadenenctomy, omentectomy, appendectomy, peritoneal biopsies; hormonal therapy |
Extension into cervix at presentation; NERM at 10 months |
| Gan et al (20) |
2007 |
40 |
NS |
Corpus |
Hysterectomy |
NERM at 16 months |
| 33 |
NS |
Corpus |
Hysterectomy |
NERM at 32 months |
||
| 44 |
NS |
Corpus |
Hysterectomy |
NERM at 52 months |
||
| Rammeh Rommani et al (21) |
2006 |
35 |
No |
Corpus |
Excision |
NERM at 4 months |
| Azad et al (22) |
2006 |
25 |
No |
Cervix |
Radical hysterectomy, Lymphadenectomy |
Unavailable or Recent |
| Folpe et al (13) |
2005 |
59 |
No |
Corpus |
Adjuvant Chemotherapy |
Liver and Lung metastases at 30 months. Alive with metastases 30 months |
| 56 |
No |
Corpus |
Adjuvant Chemotherapy and radiotherapy |
Lung and bone metastases at 11 months; Alive with metastases 11 months |
||
| 36 |
No |
Corpus |
Hysterectomy, adjuvant chemotherapy |
Lung metastases at 12 months, liver metastases 36 months; Death at 39 months |
||
| 42 |
No |
Corpus |
No additional surgery or adjuvant therapy |
NERM at 11 months |
||
| 28 |
No |
Cervix |
Hysterectomy and Lymphadenectomy |
NERM at 36 months |
||
| 48 |
No |
Cervix |
Adjuvant Radiotherapy |
NERM at 21 months |
||
| Jeon et al (23) |
2005 |
9 |
No |
Corpus |
Neoadjuvant chemotherapy, Hysterectomy with Lymphadenectomy, Adjuvant Chemotherapy/Radiotherapy |
Lymph node metastases at presentation, NERM at 18 months |
| Bernado Vega et al (27) |
2005 |
34 |
No |
Corpus |
Hysterectomy/BSO |
Unavailable or Recent |
| Bosincu et al (24) |
2005 |
59 |
No |
Corpus |
Hysterectomy/BSO, omentectomy, abdominal exploration |
Pelvic recurrence at 6 months; Death at 12 months |
| 48 |
No |
Corpus |
GnRH analogues, then Hysterectomy |
NERM at 36 months |
||
| Fukunaga (25) |
2005 |
40 |
No |
Corpus |
Hysterectomy/BSO, omentectomy, Adjuvant chemotherapy and radiation. |
Ovarian and Omental metastases at presentation, Death at 16 months |
| 30 |
No |
Corpus |
Hysterectomy |
NERM at 36 months |
||
| 36 |
No |
Corpus |
Hysterectomy |
NERM at 6 months |
||
| Fukunaga (25,26) |
2004 |
32 |
No |
Corpus |
Excision |
NERM at 12 months |
| Gao et al (28) |
2004 |
60 |
No |
Corpus |
Hysterectomy/BSO, staging |
Unavailable or Recent |
| Darai et al (29) |
2004 |
18 |
No |
Corpus |
Excision |
Pelvic recurrence and lymph node metastases, 6 months, NERM subsequent 24 months |
| Fadare et al (5) |
2004 |
41 |
Yes |
Cervix |
Hysterectomy/BSO |
NERM at 35 months |
| Dimmler et al (32) |
2003 |
61 |
NS |
Corpus |
Hysterectomy |
Lung metastases at 84 months |
| Greene et al (30) |
2003 |
79 |
NS |
Corpus |
Hysterectomy/BSO |
Pelvic and abdominal recurrence at 24 months; Death at 24+ months |
| Park et al (31) |
2003 |
32 |
No |
Corpus |
Hysterectomy/RSO |
Right broad ligament/mesovarian extension at presentation; NERM at 18 months |
| Vang & Kempson (33) |
2002 |
40 |
No |
Corpus |
Excision |
Unavailable or Recent |
| 54 |
No |
Corpus |
Hysterectomy/BSO |
Unavailable or Recent |
||
| 56 |
No |
Corpus |
Hysterectomy/BSO |
Unavailable or Recent |
||
| 75 |
No |
Corpus |
Hysterectomy/BSO, Adjuvant Radiotherapy |
NERM at 31.2 months |
||
| 47 |
No |
Corpus |
Hysterectomy/BSO |
NERM at 1.5 months |
||
| 49 |
Yes |
Corpus |
Hysterectomy/BSO |
NERM at 54 months |
||
| 55 |
No |
Corpus |
Hysterectomy/BSO |
NERM at 2 months |
||
| 58 |
No |
Corpus |
Hysterectomy/BSO |
Unavailable or Recent |
||
| Bonnetti et al (34) |
2001 |
19 |
No |
Corpus |
Hysterectomy/BSO/pelvic and inguinal lymphadenectomy, Adjuvant chemotherapy and radiotherapy |
Metastases to pelvic/inguinal nodes and vaginal extension at presentation. Local recurrence, bone and lung metastases 18 months; no further follow-up |
| 41 |
Yes |
Corpus |
Hysterectomy/BSO |
Ovarian metastases at presentation, NERM at 6 months |
||
| Michal & Zamecnik* (35) |
2000 |
58 |
No |
Corpus |
Hysterectomy |
NERM at 48 months |
| 48 |
No |
Corpus |
Hysterectomy |
NERM at 48 months |
||
| 46 |
No |
Corpus |
Hysterectomy |
NERM at 12 months |
||
| 46 |
No |
Corpus |
Hysterectomy |
NERM at 12 months |
||
| Ruco et al** (38) |
1998 |
56 |
No |
Corpus |
NS |
Ovary and ileum metastases at presentation |
| Pea et al (19) |
1996 |
57 |
No |
Corpus |
NS |
NERM at 24 months |
|
TSC tuberous sclerosis complex; BSO bilateral salpingo-oophorectomy; NERM no evidence of tumor recurrence or metastases. *these authors [35] published a subsequent opinion in which they indicated that their cases are better designated epithelioid smooth muscle neoplasia [36]. **Presumes the same case is being described in references 37 and 38. ***Includes cases published in the English literature before 01/31/08 only, and excludes the case reported in reference 53 due to lack of data. | ||||||
Fadare International Seminars in Surgical Oncology 2008 5:7 doi:10.1186/1477-7800-5-7 |
||||||
